Relapsed or Refractory B-cell Malignancies
·MeSH: Recurrence
5 drugs in development·4 companies·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| bexobrutideg | Nurix Therapeutics, Inc. (NRIX) |
Phase 1(2)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| zugo-cel | CRISPR Therapeutics AG (CRSP) |
Phase 4(1)
| Drug | Company |
|---|---|
| Acalabrutinib | ASTRAZENECA PLC (AZN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Relapsed or Refractory B-cell Malignancies?
BioSniper tracks 5 drugs in development for Relapsed or Refractory B-cell Malignancies across 4 companies.
How many clinical trials target Relapsed or Refractory B-cell Malignancies?
There are 1 clinical trial targeting Relapsed or Refractory B-cell Malignancies tracked by BioSniper.
Deep-dive into Relapsed or Refractory B-cell Malignancies
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis